COO

Business Profile & Competitive Position

The Cooper Companies, Inc. operates as a global medical device company in Healthcare, specifically the Medical – Instruments & Supplies industry. It runs two main divisions. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses and specialty eyecare products, including silicone hydrogel lenses, orthokeratology and scleral lenses, plus the MiSight 1 day lens for myopia management. CooperSurgical offers more than 600 products and services in fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services.

The company’s products reach customers in over 130 countries and touch more than 50 million lives each year, and its R&D workforce totals roughly 500 employees across both segments. MiSight 1 day holds the distinction of being approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. The profit metrics, however, temper any assumptions of a wide moat: the trailing net margin is 5.6% and return on equity is only 2.8%. Those figures suggest that scale and regulatory approvals have not translated into unusually high pricing power or capital efficiency, and that competitive pressure in contact lenses and fertility services keeps margins relatively modest.

Financial Posture

Cooper Companies currently carries a market capitalization of about $14.8 billion and trades at a trailing price-to-earnings ratio of 64.4. That P/E is notably higher than the median you would typically see in diversified medical supplies, which means the share price embeds a substantial growth premium even while net margin sits at 5.6% and ROE at 2.8%. The beta is 0.82, so the stock has historically moved a little less than the broader market, consistent with a defensive healthcare orientation. The share price most recently printed at $76.04, with the 50-day exponential moving average at $72.41 and a relative strength index of 59.0.

Putting the valuation pieces together, the market is paying a premium for future business expansion rather than current profitability. A 64.4x multiple against a 5.6% net margin and 2.8% ROE creates a wide gap between expectations and reported returns, which is the central tension anyone analyzing the stock should understand.

Strategic Priorities & Outlook

According to the company’s most recent 10-K filing, CooperVision is prioritizing greater worldwide market penetration of recently introduced products and expanding its presence in both existing and emerging markets. To support that growth, it is raising investment in distribution and packaging capabilities, and it is actively building the myopia management market through education of eye care practitioners, patients and families.

CooperSurgical, meanwhile, expects to keep investing in its business, including through strategic transactions, to broaden its integrated solutions model within fertility and women’s health. Those priorities point to a two-track growth agenda: organic product adoption and targeted M&A. The fertility side in particular relies on deal-making to expand capabilities and geographic footprint, while the vision side leans on new product uptake and practitioner education around myopia control.

Macro & Geopolitical Exposure

As a Medical – Instruments & Supplies company, Cooper Companies is exposed to the typical forces that shape regulated medical device businesses. Product approvals, quality controls and post-market surveillance by agencies such as the FDA, China’s NMPA and Japan’s MHLW affect time-to-market and commercialization costs. Reimbursement and healthcare-spending trends in major markets can influence pricing power and volume growth.

With sales in more than 130 countries, currency hedging and foreign-exchange translation are relevant considerations, as are supply-chain and logistics costs for contact-lens materials, packaging and surgical consumables. Trade policy, tariffs and shipping disruptions can ripple through margins in a low-double-digit net-margin business. Demographic tailwinds such as rising childhood myopia and delayed family planning support demand, but macro weakness can still pressure elective fertility spending and consumer contact-lens purchases.

Recent Developments

The recent news feed tied to the COO ticker has been light on company-specific catalysts. The most directly stock-relevant item is a Zacks article dated 2026-08-21, “COO vs. MMSI: Which Stock Is the Better Value Option?” The other recent headlines are not about The Cooper Companies itself but rather use “COO” to refer to the chief operating officer role elsewhere: on 2026-08-23, fool.com reported that Rigetti Computing’s COO sold over 9,000 shares; on 2026-08-19, gurufocus.com covered Target’s Q2 2026 earnings call; and on the same day 247wallst.com noted that Wendy’s jumped on a Nelson Peltz take-private report and a COO role revival.

Because these items are largely noise unrelated to Cooper’s fundamentals, they do not provide a direct read on the company’s operating trajectory. For traders, the actionable signal sits with the upcoming earnings report rather than with these headline cross-currents.

Earnings Behavior & Post-Earnings Drift

On the earnings front, Cooper Companies has delivered a perfect 8-for-8 beat rate over the last eight reported quarters, with an average earnings surprise of 4.6%. Despite that consistency, the average 5-day price move in the five trading days after those reports is -0.91%, classified as a downward post-earnings drift. That disconnect is important: the company has reliably exceeded estimates, but the positive news has often already been priced in or sold off in the sessions that followed.

The last four quarters illustrate the pattern clearly. On 2026-06-04, Cooper reported $1.21 versus a $1.10 estimate, a 10.0% beat, sending the stock up 8.58% the next day and 8.85% over the following five sessions. On 2026-03-05, it delivered $1.10 versus $1.03, a 6.8% surprise, yet the stock fell 4.55% the next day and 10.82% over five days. On 2025-12-04, $1.15 beat $1.11 by 3.6%, producing a 5.67% one-day gain and a 6.59% five-day gain. On 2025-08-27, $1.10 beat $1.07 by 2.8%, but the stock dropped 12.86% the next day and 8.24% over the next week.

Next up is the 2026-09-09 after-close report, with a published consensus EPS estimate of $1.12. Because of the 8-quarter streak, the market’s real expectation may be above that published number. Still, the historical record shows that beating estimates has not guaranteed a positive post-earnings reaction, especially given the stock’s rich valuation and the modest margin profile.

For anyone trying to weigh the streak of upside surprises against the stock’s high valuation and negative post-earnings drift, the full institutional verdict offers a deeper dive into the factors driving those dynamics without tipping into a directional call.